logo

IBIO

iBio·NASDAQ
--
--(--)
--
--(--)
0.82 / 10
Underperform

iBio's financial health scores only 0.8/10, indicating significant challenges. Key positives include a Cost of Sales ratio of 72.10% (ranked 2nd best) and an Equity Multiplier of 1.35 (also ranked 2nd), yet these are outweighed by severe negatives such as a negative ROA (-71.22%) and a deeply negative Net Profit margin on total assets (-71.22%). Historical back-tests show consistently poor monthly returns for these metrics, reinforcing the weak fundamental outlook.

Fundamental(0.82)SentimentTechnical

Analysis Checks(2/7)

ROA (%)
Value-71.22
Score0/3
Weight27.04%
1M Return-5.58%
Equity multiplier
Value1.35
Score2/3
Weight7.04%
1M Return-1.03%
Total profit (YoY growth rate %)
Value47.31
Score0/3
Weight23.04%
1M Return-3.37%
Fixed assets turnover ratio
Value0.06
Score1/3
Weight17.20%
1M Return-2.65%
Annualized net profit margin on total assets (%)
Value-71.22
Score0/3
Weight27.04%
1M Return-5.58%
Cost of sales ratio (%)
Value72.10
Score2/3
Weight-16.66%
1M Return2.10%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value61.69
Score1/3
Weight15.32%
1M Return-2.14%
Is IBIO fundamentally strong?
  • IBIO scores 0.82/10 on fundamentals and holds a Premium valuation at present. Backed by its -16.13% ROE, 0.00% net margin, -4.29 P/E ratio, 1.41 P/B ratio, and 35.19% earnings growth, these metrics solidify its Underperform investment rating.